Check out our comprehensive educational activities here

How does quizartinib fit into the treatment paradigm of AML and what are the key aspects that clinicians need to know about this agent?

In this activity, Dr. Perl explains one of the most potent and selective FLT3 inhibitors developed and where it will fit in the treatment landscape if approved.

Published on May 6, 2020 in Treatment

How are the results of the phase 3 ADMIRAL trial changing the treatment paradigm for salvage therapy of AML?

It is important to screen for FLT3 mutations in patients who have relapsed/refractory AML. Join Dr. Perl as he covers the results of the phase 3 ADMIRAL trial and how this will impact practice.

Published on May 6, 2020 in Treatment

Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Watch Dr. Daver discuss the potential of venetoclax in combination with traditional induction chemotherapy for a younger and fitter AML population.

Published on April 22, 2020 in Treatment

How to utilize and sequence new drugs in the treatment of AML

With the approval of new drugs that target specific genetic mutations, the treatment of AML has become complicated. In this activity, Dr. Stein explains how to navigate the combinations and sequences.

Published on April 10, 2020 in Treatment

Are there certain agents which could be selected for treatment which may lessen immunosuppression?

Join Dr. Pollyea as he explains selecting treatment that may lessen immunosuppression amid the COVID-19 pandemic.

Published on April 8, 2020 in Treatment

In this setting of the COVID-19 pandemic, will clinical trials continue to enroll patients?

In this activity, Dr. Pollyea explains how the COVID-19 pandemic is impacting clinical trial enrollment in AML and MDS.

Published on April 8, 2020 in Treatment

What education instruction are you providing to your patients with AML who are already immunocompromised and are you continuing treatment as planned?

Join Dr. Pollyea as he discusses how to continue treatment with your patients who are already immunocompromised during the COVID-19 pandemic.

Published on April 8, 2020 in Treatment

How are you managing care delivery during the COVID-19 pandemic?

In this activity, Dr. Pollyea explains how the COVID-19 pandemic is impacting care delivery in his patients with AML.

Published on April 8, 2020 in Treatment

What are the advantages and disadvantages of the different FLT3 inhibitors?

There are several treatment options for AML that are FDA approved. In this activity, Dr. Perl discusses each FLT3 inhibitor and how it can be implemented into treatment.

Published on April 1, 2020 in Treatment

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory AML

Dr. Daver covers the results of the phase 1b study of venetoclax in combination with gilteritinib in patients with relapsed/refractory AML and what this approval could mean for future treatment.

Published on March 23, 2020 in Treatment